Rebecca A. Makinson
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine.
Journal: Nature communications
Published: June 19, 2024
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial.
Journal: The Lancet. Microbe
Published: March 05, 2024
A Bivalent Adenovirus-Vectored Vaccine Induces a Robust Humoral Response, but Does Not Protect Cynomolgus Macaques Against a Lethal Challenge With Sudan Virus.
Journal: The Journal of infectious diseases
Published: October 26, 2023
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Journal: The Lancet. Microbe
Published: March 11, 2022
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Journal: JCI insight
Published: December 08, 2021
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.
Journal: Frontiers in immunology
Published: October 15, 2021
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal: Nature medicine
Published: May 22, 2021
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal: Nature medicine
Published: May 07, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Journal: The lancet. HIV
Published: April 19, 2021
Last Updated: 09/26/2026